In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma

Recently, two phase III studies of bevacizumab, an anti-angiogenic, for newly diagnosed glioblastoma (GBM) patients were released. While they were unable to statistically significantly demonstrate that bevacizumab in combination with other therapies increases the overall survival of GBM patients, th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J R Soc Interface
Main Authors: Hawkins-Daarud, Andrea, Rockne, Russell, Corwin, David, Anderson, Alexander R. A., Kinahan, Paul, Swanson, Kristin R.
Formato: Artigo
Idioma:Inglês
Publicado em: The Royal Society 2015
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4535409/
https://ncbi.nlm.nih.gov/pubmed/26202682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1098/rsif.2015.0388
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados